DAE HWA Pharmaceutical Co. Ltd Asset Resilience Ratio
DAE HWA Pharmaceutical Co. Ltd asset resilience ratio. DAE HWA Pharmaceutical Co. Ltd (067080) has an Asset Resilience Ratio of 2.45% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 067080 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of DAE HWA Pharmaceutical Co. Ltd (2011–2025)
Asset resilience ratio of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025. This chart shows how DAE HWA Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. Read DAE HWA Pharmaceutical Co. Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down DAE HWA Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see DAE HWA Pharmaceutical Co. Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩5.41 Billion | 2.45% |
| Total Liquid Assets | ₩5.41 Billion | 2.45% |
Asset Resilience Insights
- Limited Liquidity: DAE HWA Pharmaceutical Co. Ltd maintains only 2.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
DAE HWA Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio
Compare DAE HWA Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
DAE HWA Pharmaceutical Co. Ltd Asset Resilience Ratio by Year (2011–2025)
DAE HWA Pharmaceutical Co. Ltd asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for DAE HWA Pharmaceutical Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.25% | ₩4.75 Billion ≈ $3.22 Million |
₩210.86 Billion ≈ $142.90 Million |
+0.92pp |
| 2024-12-31 | 1.33% | ₩2.74 Billion ≈ $1.85 Million |
₩205.88 Billion ≈ $139.52 Million |
-1.32pp |
| 2023-12-31 | 2.64% | ₩5.80 Billion ≈ $3.93 Million |
₩219.16 Billion ≈ $148.52 Million |
+0.29pp |
| 2022-12-31 | 2.35% | ₩4.68 Billion ≈ $3.17 Million |
₩199.06 Billion ≈ $134.90 Million |
-4.56pp |
| 2021-12-31 | 6.91% | ₩12.26 Billion ≈ $8.31 Million |
₩177.38 Billion ≈ $120.21 Million |
+3.29pp |
| 2020-12-31 | 3.62% | ₩6.34 Billion ≈ $4.29 Million |
₩175.05 Billion ≈ $118.63 Million |
-1.71pp |
| 2019-12-31 | 5.33% | ₩8.86 Billion ≈ $6.01 Million |
₩166.15 Billion ≈ $112.59 Million |
-4.60pp |
| 2018-12-31 | 9.94% | ₩16.10 Billion ≈ $10.91 Million |
₩162.06 Billion ≈ $109.82 Million |
+1.20pp |
| 2017-12-31 | 8.74% | ₩14.46 Billion ≈ $9.80 Million |
₩165.47 Billion ≈ $112.14 Million |
-0.86pp |
| 2016-12-31 | 9.60% | ₩14.76 Billion ≈ $10.00 Million |
₩153.80 Billion ≈ $104.23 Million |
+7.81pp |
| 2015-12-31 | 1.79% | ₩2.23 Billion ≈ $1.51 Million |
₩124.61 Billion ≈ $84.45 Million |
-1.38pp |
| 2014-12-31 | 3.17% | ₩3.93 Billion ≈ $2.66 Million |
₩124.07 Billion ≈ $84.08 Million |
+1.80pp |
| 2013-12-31 | 1.37% | ₩1.67 Billion ≈ $1.13 Million |
₩121.87 Billion ≈ $82.59 Million |
-1.15pp |
| 2012-12-31 | 2.52% | ₩3.27 Billion ≈ $2.22 Million |
₩130.19 Billion ≈ $88.23 Million |
-1.88pp |
| 2011-12-31 | 4.39% | ₩5.96 Billion ≈ $4.04 Million |
₩135.58 Billion ≈ $91.88 Million |
-- |
About DAE HWA Pharmaceutical Co. Ltd
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthriti… Read more